UniQure to Submit Huntington's Disease Therapy for FDA Approval
Biotech company UniQure plans to submit its experimental treatment for Huntington's disease for U.S. regulatory approval. This development follows a reversal by the U.S. Food and Drug Administration (FDA) regarding its previous opposition to the therapy, effectively clearing the path for UniQure's filing. Separately, pharmaceutical giant Eli Lilly has completed the acquisition of 4E Therapeutics.
Biotech firm UniQure has announced its intention to submit an experimental treatment for Huntington's disease for U.S. approval. The company stated that the U.S. Food and Drug Administration (FDA) has reversed its previous opposition to this closely watched therapy.
The FDA's decision clears the way for UniQure to file for U.S. regulatory approval for its treatment. Huntington's disease is a progressive neurodegenerative genetic disorder.
In related industry news, Eli Lilly has acquired 4E Therapeutics.
According to STAT News, UniQure confirmed these developments.
